Volume 27, Issue 1 - Vaccines and Immunotherapies

Immuno-oncology: Harnessing our immune system to fight cancer

Authors: Anne Rascle, Trevor Stanbury

Abstract

Download the full article

References

1. Faries MB. Intralesional Immunotherapy for metastatic melanoma: the oldest and newest treatment in oncology. Crit Rev Oncog. 2016;21:65–73.
2. Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529–64.
3. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am J Med Sci. 1893;105:487–511.
4. Morrissey KM, Yuraszeck TM, Li C-C, et al. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci. 2016;9:89–104.
5. Mataraza JM, Gotwals P. Recent advances in immuno-oncology and its application to urological cancers. BJU Int. 2016;118: 506–14.
6. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1–14.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
8. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–89.
9. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
10. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23:975–1028.
11. Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res. 1997;27:81–6.
12. Darrasse-Jèze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med. 2009;206:1853–62.
13. Kober J, Leitner J, Klauser C, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol. 2008;38:2678–88.
14. Croft M, So T, Duan W, et al. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229:173–91.
15. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4: 762–74.
16. Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–79.
17. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mecha - nism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.
18. Bouzin C, Brouet A, De Vriese J, et al. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178:1505–11.
19. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226–30.
20. Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401–9.
21. Ohta A. A Metabolic Immune checkpoint: adenosine in tumor microenvironment. Front Immunol. 2016;7:109.
22. Kamta J, Chaar M, Ande A, et al. Advancing cancer therapy with present and emerging immuno-oncology approaches. Front Oncol. 2017;7:64.
23. Galluzzi L, Vacchelli E, Bravo-San Pedro J-M, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–508.
24. Kokate R. A systematic overview of cancer immunotherapy: an emerging therapy. Pharm Pharmacol Int J. 2017;5:1–6.
25. Prowell TM, Theoret MR, Pazdur R. Seamless oncology-drug development. N Engl J Med. 2016;374:2001–3.
26. Menis J, Litière S, Tryfonidis K, et al. The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Ann Transl Med. 2016;4:267
27. Emens LA, Butterfield LH, Hodi FS, et al. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016;4:42.
28. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
29. Kohrt HE, Tumeh PC, Benson D, et al. Immunodynamics: a cancer immuno - therapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016;4:15.
30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl. 1990 2009;45:228–47.
31. Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281–9.
32. Le Lay J, Jarraya H, Lebellec L, et al. irRECIST and iRECIST: the devil is in the details. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:1676–8.
33. Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer Oxf Engl 2017;88:38–47.
34. Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? Ecancermedicalscience. 2015;9:604.
35. Hodi FS, Hwu W-J, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1510–7.
36. Wang P-F, Chen Y, Song S-Y, et al. Immunerelated adverse events associated with anti- PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730.
37. Haanen JB a. G, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:iv119-iv142.
38. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14: E10–21.
39. Roselló S, Blasco I, García Fabregat L, et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:iv100- iv118.
40. Regis SM. Patient navigation in immunooncology. Am J Manag Care. 2017;23:SP46–7.
41. Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti- PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.